Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Sandoz B2B

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

    Impressions: 773

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

    Radio Compass
    12 Mar 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

    AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

    Artificial intelligence (AI) is emerging as a transformative force in drug discovery and development. The global AI in drug discovery market was valued at US$ 1.99 billion in 2024 and is estimated to reach US$ 2.65 billion in 2025. Going forward, the market is expected to grow at an impressive compounded annual growth rate (CAGR) of 29.6 percent, to reach a market size of US$ 35.42 billion by 2034, says a report by Polaris Market Research. This growth expectation mirrors the eagerness within the biopharma industry to leverage AI in order to overcome the traditional barriers of lengthy timelines, exorbitant costs, and high failure rates. This eagerness is also being manifested in deal making — Big Pharma has been busy forging alliances with AI-driven drug discovery companies. Over the last two years, almost every big drugmaker, including Novo Nordisk, Merck, BMS, Pfizer, AstraZeneca, Otsuka Pharmaceutical, Novartis and Sanofi, has signed deals with various AI drug discovery companies. PharmaCompass' compilation shows there are scores of molecules discovered by AI currently in discovery and developmental phases, demonstrating the technology's growing impact on pharmaceutical pipelines.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available) Novo, Lilly, BMS invest in AI partnerships; Recursion, Exscientia merge to create AI powerhouse With the transformative potential of AI becoming increasingly evident, we witnessed a slew of deals in the biopharma industry over the last six months. A significant deal in the AI drug discovery space was the merger of two leaders — Recursion and Exscientia — that took place in November last year. Exscientia is now a wholly-owned subsidiary of Recursion. The merger has created a global technology-enabled drug discovery leader with end-to-end capabilities. The merged entity has over 10 clinical and preclinical programs, and around 10 advanced discovery programs in the pipeline.  Apart from this merger, several large drugmakers have struck deals with AI drug discovery firms since September last year. For instance, in January this year, Valo Health and Novo Nordisk expanded their collaboration to discover and develop novel treatments for cardiometabolic diseases. This deal, valued at up to US$ 4.8 billion, aims to harness the power of AI and extensive human datasets. Building on their initial 2023 partnership, it will enable the development of up to 20 drug programs.  Similarly, Pfizer, which is already big on AI, extended its AI drug discovery pact with PostEra and also partnered IgnitionAI to enhance drug discovery — all within the last six months. And Novartis struck a drug discovery deal with Generate BioMedicines in September. Insilico Medicine has been actively forging partnerships. In January, Insilico entered a second exclusive global license agreement with Menarini Group for an AI-discovered preclinical asset targeting high unmet needs in oncology. Insilico also has a tie-up with Sanofi, dating back to 2022. In December 2024, AI Proteins announced a research collaboration and option agreement with BMS to design and optimize mini-proteins for therapeutic use. And in September, Eli Lilly joined hands with Genetic Leap to accelerate the development of genetic medicines. Lilly will leverage Genetic Leap’s RNA-targeted AI platform to generate oligonucleotide drugs against selected targets.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  AI leads to faster target identification; Insilico, BenevolentAI’s candidates in trials Computational biology, and especially AI, has fundamentally changed the drug discovery paradigm. The traditional method of drug discovery used to take 13 to 15 years, costing an average of US$ 2.5 billion in investment before a drug got approved and launched in the market. Additionally, less than 10 percent of candidates in phase 1 clinical trials used to end up getting approved by the US Food and Drug Administration (FDA). All that has begun to change. According to Khair ElZarrad, Director of the Office of Medical Policy within FDA’s Center for Drug Evaluation and Research, since 2016, FDA has received approximately 300 submissions that reference AI use as of May 2024. These submissions range from drug development, drug discovery, clinical research, clinical trials as well as post-market safety surveillance and manufacturing. Though we are yet to witness an AI-generated candidate translate into an approved therapy, target identification in drug discovery is visibly becoming a lot faster. This is the process that identifies specific molecules or pathways in the human body that are linked to a disease. The best example of dramatic acceleration of timelines is Insilico Medicine’s development of INS018_055, a candidate for idiopathic pulmonary fibrosis that entered phase 2 trials in June 2023. Using their AI platform PandaOmics, researchers at Insilico compressed target identification from years to just 18 months. Similarly, BenevolentAI successfully employed their AI platform to identify a new target for ulcerative colitis, leading to the development of BEN-8744, a candidate that has been in phase 1a clinical trials since August 2023.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  Oncology leads AI drug discovery market; Recursion shows how to repurpose drugs using AI The integration of AI in oncology research has been impactful, accounting for the largest revenue share (about 22.4 percent) in the AI drug discovery market in 2023. AI technologies have accelerated the discovery and development of new cancer treatments, bolstered personalized medicine approaches, and improved clinical trial designs in the arena of this complex disease.  Another promising application is drug repurposing, where AI can identify new therapeutic applications for existing drugs. Recursion Pharmaceuticals’ REC-2282 exemplifies this approach. This therapy is currently in phase 2/3 studies for neurofibromatosis type 2 (a genetic condition that causes tumors to grow along nerves). By repurposing compounds already vetted for safety, this strategy can bypass early-stage failures, reducing both time and cost compared to developing entirely new molecules. However, the use of AI in drug discovery is not without challenges. Exscientia’s EXS-21546, designed to treat solid tumors, entered phase 1/2 trials in 2020 but was discontinued in 2023 after modeling suggested that achieving a suitable therapeutic index would be difficult. Though this is a clinical failure, it highlights AI’s value in identifying potential failures earlier on in the development process, saving resources that would have otherwise been spent on later-stage trials.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  Our view The Covid-19 pandemic was a time when humanity felt the urgent need to speed up the process of drug discovery, testing and approvals. It also hastened the process of integrating AI into pharmaceutical research, leading to the launch of Covid vaccines in record time. Today, there is no looking back — AI is bringing about a paradigm shift in how drugs are discovered. With increasing reliance on AI, there is hope that drug discovery will be more accurate, efficient and less time and cost consuming.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1262

    https://www.pharmacompass.com/radio-compass-blog/ai-drug-discovery-market-to-grow-30-cagr-to-reach-us-35-bn-by-2034-novo-lilly-bms-forge-deals

    #PharmaFlow by PHARMACOMPASS
    13 Mar 2025
    Share Share

    NEWS #PharmaBuzz

    [Sponsored by another company]read-more
    read-more
    20 US states balk at Florida settlement with Sandoz
    20 US states balk at Florida settlement with Sandoz

    18 Mar 2025

    // REUTERS

    https://www.reuters.com/legal/government/20-us-states-balk-florida-settlement-with-drugmaker-sandoz-2025-03-18/

    REUTERS
    18 Mar 2025
    Share Share
    Sandoz reports strong FY 2024 results and Q4 2024 sales
    Sandoz reports strong FY 2024 results and Q4 2024 sales

    05 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/05/3037092/0/en/Sandoz-reports-strong-FY-2024-results-and-Q4-2024-sales.html

    GLOBENEWSWIRE
    05 Mar 2025
    Share Share
    Avecho, Sandoz Partner To Develop CBD For Insomnia In Australia
    Avecho, Sandoz Partner To Develop CBD For Insomnia In Australia

    03 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avecho-and-sandoz-enter-exclusive-license-and-development-agreement-to-commercialise-cbd-for-insomnia-in-australia-302390680.html

    PR NEWSWIRE
    03 Mar 2025
    Share Share
    Avecho and Sandoz sign exclusive CBD licensing deal for insomnia
    Avecho and Sandoz sign exclusive CBD licensing deal for insomnia

    03 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avecho-and-sandoz-enter-exclusive-license-and-development-agreement-to-commercialise-cbd-for-insomnia-in-australia-302390766.html

    PR NEWSWIRE
    03 Mar 2025
    Share Share
    Sandoz launches biosimilar Pyzchiva in the US
    Sandoz launches biosimilar Pyzchiva in the US

    24 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/24/3030856/0/en/Sandoz-launches-biosimilar-Pyzchiva-ustekinumab-ttwe-in-the-US-offering-new-treatment-for-around-12-million-patients-1-4.html

    GLOBENEWSWIRE
    24 Feb 2025
    Share Share
    Sandoz`s Biologic Enzeevu Receives Suppl Approval in US
    Sandoz`s Biologic Enzeevu Receives Suppl Approval in US

    10 Feb 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761382

    FDA
    10 Feb 2025
    Share Share
    Contact Sandoz B2b and get a quotation

    Sandoz B2b is a supplier offers 143 products (APIs, Excipients or Intermediates).

    Find a price of Amoxicillin Trihydrate bulk with DMF, CEP, JDMF offered by Sandoz B2b

    Find a price of Ampicillin Sodium bulk with DMF, CEP, JDMF offered by Sandoz B2b

    Find a price of Levothyroxine Sodium bulk with DMF, CEP, JDMF offered by Sandoz B2b

    Find a price of Penicillin G Potassium bulk with DMF, CEP, JDMF offered by Sandoz B2b

    Find a price of Amoxicillin Trihydrate bulk with DMF, JDMF offered by Sandoz B2b

    Find a price of Cefpodoxime Proxetil bulk with CEP, JDMF offered by Sandoz B2b

    Find a price of Penicillin G Potassium bulk with CEP, JDMF offered by Sandoz B2b

    Find a price of Amoxicillin Sodium bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Ampicillin bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Ampicillin Trihydrate bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Benzylpenicillin Sodium bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Cefazolin Sodium bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Ceftazidime bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Ceftriaxone bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Clavulanic Acid bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Cloxacillin Sodium bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Penicillin G Benzathine bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Penicillin G Procaine bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Penicillin V Potassium bulk with DMF, CEP offered by Sandoz B2b

    Find a price of Cefixime bulk with DMF offered by Sandoz B2b

    Find a price of Cefixime bulk with CEP offered by Sandoz B2b

    Find a price of Cefotaxime bulk with DMF offered by Sandoz B2b

    Find a price of Cefpodoxime Proxetil bulk with DMF offered by Sandoz B2b

    Find a price of Clavulanic Acid bulk with DMF offered by Sandoz B2b

    Find a price of 1H-Imidazo 1 2-A Pyridin-4-Ium bulk with DMF offered by Sandoz B2b

    Find a price of 6-Aminopenicillanic Acid bulk with DMF offered by Sandoz B2b

    Find a price of 7-Amca bulk with DMF offered by Sandoz B2b

    Find a price of 7-Amino Cephalosporanic Acid bulk with DMF offered by Sandoz B2b

    Find a price of Amoxicillin Sodium bulk with CEP offered by Sandoz B2b

    Find a price of Azithromycin bulk offered by Sandoz B2b

    Find a price of CAS 24280-93-1 bulk with DMF offered by Sandoz B2b

    Find a price of Cefdinir bulk with DMF offered by Sandoz B2b

    Find a price of Cefepime bulk offered by Sandoz B2b

    Find a price of Cefozopran Hydrochloride bulk with JDMF offered by Sandoz B2b

    Find a price of Ceftazidime bulk with DMF offered by Sandoz B2b

    Find a price of Cefuroxime Axetil bulk offered by Sandoz B2b

    Find a price of Cephalosporin C Sodium bulk with DMF offered by Sandoz B2b

    Find a price of Clarithromycin bulk offered by Sandoz B2b

    Find a price of Clofazimine bulk with DMF offered by Sandoz B2b

    Find a price of Erythromycin bulk offered by Sandoz B2b

    Find a price of Erythromycin Ethyl Succinate bulk offered by Sandoz B2b

    Find a price of Heparin Sodium bulk with DMF offered by Sandoz B2b

    Find a price of Imipenem bulk offered by Sandoz B2b

    Find a price of Immunomycin bulk with DMF offered by Sandoz B2b

    Find a price of Lansoprazole bulk offered by Sandoz B2b

    Find a price of Liothyronine Sodium bulk offered by Sandoz B2b

    Find a price of Omeprazole bulk offered by Sandoz B2b

    Find a price of PACA bulk with DMF offered by Sandoz B2b

    Find a price of Phenoxymethylpenicilline Benzathine Tetrahydrate bulk with CEP offered by Sandoz B2b

    Find a price of Piperacillin + Tazobactam bulk with DMF offered by Sandoz B2b

    Find a price of Piperacillin Sodium bulk with DMF offered by Sandoz B2b

    Find a price of Simvastatin bulk offered by Sandoz B2b

    Find a price of Sirolimus bulk with DMF offered by Sandoz B2b

    Find a price of Sodium Dicloxacillin bulk offered by Sandoz B2b

    Find a price of Temsirolimus bulk with DMF offered by Sandoz B2b

    Find a price of VICA CRUDE bulk with DMF offered by Sandoz B2b

    Find a price of VICA (PURE) bulk with DMF offered by Sandoz B2b

    Find a price of VICA, PURE (3-VINYL-ACA) bulk with DMF offered by Sandoz B2b

    Find a price of Amoxicillin trihydrate, Powder, direct compression, compacted and microfine bulk with CEP offered by Sandoz B2b

    Find a price of Ampicillin sodium, Sterile, Enzymatic route bulk with CEP offered by Sandoz B2b

    Find a price of Ampicillin bulk offered by Sandoz B2b

    Find a price of Benzylpenicillin Sodium bulk offered by Sandoz B2b

    Find a price of Bopindolol bulk offered by Sandoz B2b

    Find a price of Butalbital bulk offered by Sandoz B2b

    Find a price of Cefixime bulk offered by Sandoz B2b

    Find a price of Cefotaxime bulk offered by Sandoz B2b

    Find a price of Cefprozil bulk offered by Sandoz B2b

    Find a price of Ceftriaxone bulk offered by Sandoz B2b

    Find a price of Chlorpheniramine Maleate bulk offered by Sandoz B2b

    Find a price of Chlorthalidone bulk offered by Sandoz B2b

    Find a price of Cilastatin Sodium bulk offered by Sandoz B2b

    Find a price of Cloxacillin Sodium bulk offered by Sandoz B2b

    Find a price of Clozapine bulk offered by Sandoz B2b

    Find a price of Cyclobenzaprine bulk offered by Sandoz B2b

    Find a price of Cyclosporine bulk offered by Sandoz B2b

    Find a price of Deacetyl-7-Aminocephalosporanic Acid bulk offered by Sandoz B2b

    Find a price of Dibenzsuberone bulk offered by Sandoz B2b

    Find a price of Doripenem bulk offered by Sandoz B2b

    Find a price of Escitalopram Oxalate bulk offered by Sandoz B2b

    Find a price of Esomeprazole Magnesium bulk offered by Sandoz B2b

    Find a price of Etoposide bulk offered by Sandoz B2b

    Find a price of Filgrastim bulk offered by Sandoz B2b

    Find a price of Flucloxacillin Sodium bulk offered by Sandoz B2b

    Find a price of Gabapentin bulk offered by Sandoz B2b

    Find a price of Guanfacine bulk offered by Sandoz B2b

    Find a price of L-Arginine Hydrochloride API bulk offered by Sandoz B2b

    Find a price of L-Leucine Hydrochloride bulk offered by Sandoz B2b

    Find a price of Lactic Acid bulk offered by Sandoz B2b

    Find a price of Lorazepam bulk offered by Sandoz B2b

    Find a price of Meropenem bulk offered by Sandoz B2b

    Find a price of Mycophenolic Acid bulk offered by Sandoz B2b

    Find a price of N-Butyl-6-Methylergoline-8-Carboxamide bulk offered by Sandoz B2b

    Find a price of Nafcillin bulk offered by Sandoz B2b

    Find a price of Nafcillin Sodium bulk offered by Sandoz B2b

    Find a price of NAFTIFINE HCL bulk offered by Sandoz B2b

    Find a price of Nitrofurantoin bulk offered by Sandoz B2b

    Find a price of Omeprazole Magnesium bulk offered by Sandoz B2b

    Find a price of Omeprazole Sodium bulk offered by Sandoz B2b

    Find a price of Oxacillin Sodium bulk offered by Sandoz B2b

    Find a price of Oxazepam bulk offered by Sandoz B2b

    Find a price of Oxytetracycline Hydrochloride bulk offered by Sandoz B2b

    Find a price of PACA bulk offered by Sandoz B2b

    Find a price of Pancrelipase bulk offered by Sandoz B2b

    Find a price of Pantoprazole Sodium bulk offered by Sandoz B2b

    Find a price of Penicillin G Benzathine bulk offered by Sandoz B2b

    Find a price of Pheniramine Maleate bulk offered by Sandoz B2b

    Find a price of Physostigmine Salicylate bulk offered by Sandoz B2b

    Find a price of Pyrilamine Maleate bulk offered by Sandoz B2b

    Find a price of Rabeprazole Sodium bulk offered by Sandoz B2b

    Find a price of Recombinant Human Growth Hormone bulk offered by Sandoz B2b

    Find a price of Rosiglitazone Maleate bulk offered by Sandoz B2b

    Find a price of Roxithromycin bulk offered by Sandoz B2b

    Find a price of Rs-86 Hydrobromide bulk offered by Sandoz B2b

    Find a price of Sertraline Hydrochloride bulk offered by Sandoz B2b

    Find a price of Sodium Carbonate bulk offered by Sandoz B2b

    Find a price of Sulbactam Sodium bulk offered by Sandoz B2b

    Find a price of Sulfamethoxazole bulk offered by Sandoz B2b

    Find a price of Temazepam bulk offered by Sandoz B2b

    Find a price of Teniposide bulk offered by Sandoz B2b

    Find a price of Thiamylal bulk offered by Sandoz B2b

    Find a price of Thiethylperazine Maleate bulk offered by Sandoz B2b

    Find a price of Thiopental Sodium bulk offered by Sandoz B2b

    Find a price of Tiamulin Fumarate bulk offered by Sandoz B2b

    Find a price of Tizanidine HCl bulk offered by Sandoz B2b

    Find a price of Venlafaxine Hydrochloride bulk offered by Sandoz B2b

    Find a price of SACA SODIUM SALT bulk offered by Sandoz B2b

    Find a price of LORAZETYL bulk offered by Sandoz B2b

    Find a price of RS-86 AMPULS 10 mg/ml AS PRODUCED IN THE BASLE, SWITZERLAND PLANT bulk offered by Sandoz B2b

    Find a price of CEFUROXIME bulk offered by Sandoz B2b

    Find a price of SDZ PSC 833 bulk offered by Sandoz B2b

    Find a price of INVESTIGATIONAL DRUGS bulk offered by Sandoz B2b

    Find a price of TDM-85-530 b bulk offered by Sandoz B2b

    Find a price of SF86-327 (E)-N-(6,6-DIMETHYL-2-HEPTEN-4-YUL)-N--METHYL-1-NAPHTHALALENE bulk offered by Sandoz B2b

    Find a price of FACILITIES AND PROCEDURES IN WHITBY, ONTARIO, CANADA. bulk offered by Sandoz B2b

    Find a price of PHENYLALANINE-METHYLAMINOCYCLOL HCL bulk offered by Sandoz B2b

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND GENERAL OPERATING PROCEDURES IN BASLE, SWITZERLAND. bulk offered by Sandoz B2b

    Find a price of RS-86 CAPSULES IN 0.25 mg AND 1.0 mg (BASLE, SWITZERLAND PLANT) bulk offered by Sandoz B2b

    Find a price of ACEPAM bulk offered by Sandoz B2b

    Find a price of FACILITIES AND PROCEDURES IN NUREMBERG, GERMANY bulk offered by Sandoz B2b

    Find a price of Co-amoxiclav bulk offered by Sandoz B2b

    Find a price of Gentamicin Sulfate bulk offered by Sandoz B2b

    Find a price of Penicillin V bulk offered by Sandoz B2b

    Find a price of Penicillin V Benzathine bulk offered by Sandoz B2b